問卷

TPIDB > Search Result

Search Result

篩選

List

3348Cases

2021-09-01 - 2024-05-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2020-09-01 - 2025-07-29

Phase II

Completed
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
  • Condition/Disease

    Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

  • Test Drug

    NIS793PDR001

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2025-07-01 - 2030-12-12

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-12-01 - 2030-03-19

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-06-25 - 2024-01-04

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-08-15 - 2026-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-10-28 - 2025-11-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2023-12-01 - 2032-12-31

Phase IV

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2026-01-26 - 2031-01-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2025-07-18 - 2029-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites